ScienceDirect - Search Results: TITL-ABS-KEY-AUT(hiv AND liver) Register or Login: Password: Athens/Institution Login Quick Search: within All Full-text Sources results 1 - 3 3 Articles Found TITL-ABS-KEY-AUT(hiv AND liver) [All Full-text Sources (- All Sciences -)] Quick Search searches the abstracts, titles, keywords, and authors within the selected content. Sort By: Date Relevance 1. HCV virological assessment • ARTICLE Journal of Hepatology, Volume 44, Supplement 1, 2006, Pages S35-S39 Xavier Forns and Josep Costa Abstract | Full Text + Links | PDF (97 K) Virological assessment of HCV infection relies on a series of assays that are essential for diagnostic purposes and to adopt therapeutic decisions. Diagnostic assays can be classified in three groups: assays that are designed to detect specific antibodies to HCV; techniques that detect and quantify viral load; and tests aimed at determining the infecting HCV type. In general, the use of these assays is similar in HCV infected patients as in those co-infected with HCV and HIV. Co-infected patients, however, have some inherent characteristics (deficient immune status, high HCV-RNA concentrations, particular genotype distribution, low response to antiviral therapy) that make the interpretation of such assays slightly different. Regarding assays to detect antibodies to HCV, last generation tests have a similar sensitivity in mono-infected and co-infected individuals. HCV-RNA testing might be helpful in anti-HCV negative individuals with clinical or analytical suspicion of liver disease. Genotype determination in patients co-infected with HCV and HIV should be performed by methods relying on sequence analysis, since serotyping assays have shown a lower sensitivity in co-infected cohorts. HCV-RNA concentration is a strong predictor of response to therapy. Due to the higher viral load of co-infected patients compared to HCV mono-infected individuals, those assays with a wide dynamic range seem more appropriate to monitor viral load during treatment. 2. Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates • ARTICLE Journal of Hepatology, Volume 44, Supplement 1, 2006, Pages S44-S48 Vincent Soriano Abstract | Full Text + Links | PDF (110 K) Recent evidence suggests that when HCV therapy is administered adequately (full doses of ribavirin, satisfactory drug compliance, and for at least 12 months irrespective of the HCV genotype) and to the appropriate co-infected candidates, treatment responses may be similar to those seen in HCV mono-infected individuals. The best responders are co-infected individuals under 40 years old with HCV genotypes 2 or 3, low HCV viral load, no cirrhosis, elevated ALT levels, elevated CD4 counts, and low or undetectable plasma HIV-RNA. Treatment should be considered in antiretroviral-naïve co-infected patients with stable HIV infection. In patients already on antiretroviral therapy, HCV therapy should only be administered after replacing ddI by another antiretroviral drug. In patients with evidence of advanced liver fibrosis, HCV therapy should be considered as a priority. However, patients with decompensated cirrhosis should not be treated. In patients with CD4 counts <200 cells/μl and/or plasma HIV-RNA above 100,000 copies/ml, it may be better to consider suppression of HIV replication before beginning HCV therapy. Individuals with a history of severe neuropsychiatric disorders, people who consume a lot of alcohol and those addicted to illegal drugs generally should not be considered suitable for HCV treatment, and efforts should be concentrated on detoxification programmes. 3. Treatment algorithm for the management of hepatitis C in HIV-coinfected persons • ARTICLE Journal of Hepatology, Volume 44, Supplement 1, 2006, Pages S49-S55 Mark S. Sulkowski Abstract | Full Text + Links | PDF (850 K) In the era of highly effective antiretroviral therapy (ART), HCV-related liver disease has emerged as a significant cause of morbidity and mortality. Accordingly, expert panels have recommend that coinfected patients undergo medical evaluation for HCV-related liver disease, consideration for HCV treatment and, if indicated, orthotopic liver transplantation. While the treatment of such patients is complicated by medical, and psychiatric comorbidities, HIV disease, and concurrent antiretroviral therapy, randomized controlled trials support the safety, tolerability and efficacy of HCV treatment with peginterferon alfa (PEG-IFN) plus ribavirin (RBV) in HIV-infected persons. Although, the available data has led to consensus among experts regarding the need to medically manage HCV disease in HIV-infected persons, uncertainty remains regarding the best treatment algorithm for coinfected patients. 3 Articles Found TITL-ABS-KEY-AUT(hiv AND liver) [All Full-text Sources (- All Sciences -)] Quick Search searches the abstracts, titles, keywords, and authors within the selected content. results 1 - 3 Contact Us | Terms & Conditions | Privacy Policy Copyright © 2006 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.